Published online Feb 26, 2024. doi: 10.12998/wjcc.v12.i6.1104
Peer-review started: December 7, 2023
First decision: December 17, 2023
Revised: December 18, 2023
Accepted: January 31, 2024
Article in press: January 31, 2024
Published online: February 26, 2024
Acute pancreatitis, an infrequent extrapulmonary manifestation of coronavirus disease 2019 (COVID-19), raises uncer
No prior literature explores the occurrence of acute pancreatitis in the kidney transplant population in the context of COVID-19.
To describe the occurrence, clinical presentation and outcomes of acute pancreatitis in a cohort of kidney transplant re
A retrospective observational single-center cohort study conducted at a single transplant center in Croatia, encompassing all adult renal transplant recipients with a functioning kidney allograft between March 2020 and August 2022. Data, in
Out of 1432 renal allograft recipients, 28.49% developed COVID-19. Hospitalization was necessary for 39.1% of patients, with 44.1% developing pneumonia and 1.3% requiring mechanical ventilation. Treatment involved immunosuppression modification in 77.1% and remdesivir in 16.6%, alongside other supportive measures. Acute pancreatitis occurred in one transplant recipient (0.3%). The patient recovered without complications, maintaining stable kidney allograft function.
Although uncommon, acute pancreatitis may complicate the course of acute COVID-19 in kidney transplant recipients.
Further research is warranted to explore the mechanism of pancreatic injury and its correlation with the severity of COVID-19 infection in kidney transplant recipients.